Latest articles
No of your stocks has realtime/relevant news articles that can be accessed.
Take a look into our News feed to read about recent price changes and analysis.
Sentiment statistics ?
Financial Histories
Please use our Financial history templates to chart, read and compare all 10'Q filings in depth.
Overview
UCBJFDay performance
| UCBJF | |
|---|---|
| Price | 72.25 |
| Change Pct | 0.00 |
| Change Abs | 0.00 |
| Market Cap | 14.3 billion |
| Eps | 1.86 |
| Pe Ratio | 38.84 |
| Outstanding Shares | 197.8 million |
| Volume | 4297 |
| Avg Volume | 339 |
| Industry | Biotechnology |
| Sector Name | Health Care |
| Country Short Name | BE |
| Announcement Earnings | null |
Dividends
There is no dividend data to display. Refer our Dividend calendar for other accurate data.
Risk Profiles
Please sign up and become a member to view all risk profiles.
Peers
The peer analysis is for none of your tickers available
Focus
Use our 'Focus' approach as text-and chart based summaries of the financial standing for a company. They are solely focussing on the company's market, risks and chances.
Company descriptions
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome;